Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis

Original Article from The New England Journal of Medicine - Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Saved in:

Bibliographic Details
Main Authors:	Adams, David B. (Author) , Kristen, Arnt (Author)
Format:	Article (Journal)
Language:	English
Published:	July 5, 2018
In:	The New England journal of medicine Year: 2018, Volume: 379, Issue: 1, Pages: 11-21
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1716153
Online Access:	Verlag, Volltext: https://doi.org/10.1056/NEJMoa1716153 Verlag, Volltext: https://www.nejm.org/doi/10.1056/NEJMoa1716153
Author Notes:	D. Adams, A. Gonzalez-Duarte, W.D. O’Riordan, C.-C. Yang, M. Ueda, A.V. Kristen, I. Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. Planté-Bordeneuve, M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan III, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, and O.B. Suhr

Description
Summary:	Original Article from The New England Journal of Medicine - Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Item Description:	Gesehen am 07.05.2019
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1716153